These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 362629)

  • 1. Diagnostic and prognostic value of donor-specific posttransplant immune responses: clinical correlates and in vitro variables.
    Stiller CR; Sinclair NR; McGirr D; Jevnikar A; Ulan RA
    Transplant Proc; 1978 Sep; 10(3):525-30. PubMed ID: 362629
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement-dependent cytotoxicity detected by 51Cr release: a predictor of kidney graft rejection.
    McConnachie PR; Finch WT; Birtch AG
    Transplant Proc; 1984 Dec; 16(6):1448-50. PubMed ID: 6390846
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic monitoring of marrow graft recipients following transplantation from HLA-identical siblings.
    Warren RP; Storb R; Weiden PL; Su PJ; Thomas ED
    Transplant Proc; 1978 Sep; 10(3):535-6. PubMed ID: 362631
    [No Abstract]   [Full Text] [Related]  

  • 4. Donor-specific monitoring of transplant patients.
    Dossetor JB; Kovithavongs T; Schlaut J; Pazderka V; Liburd EM; Bettcher KB; Pazderka F
    Transplant Proc; 1979 Jun; 11(2):1235-6. PubMed ID: 382496
    [No Abstract]   [Full Text] [Related]  

  • 5. Donor-specific cell-mediated cytotoxicity in renal allograft recipients.
    Dickmeiss E
    Acta Pathol Microbiol Scand C; 1979 Dec; 87(6):371-76. PubMed ID: 397716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant immunologic monitoring of the renal allograft recipient.
    Gailiunas P; Suthanthiran M; Person A; Strom TB; Carpenter CB; Garovoy MR
    Transplant Proc; 1978 Sep; 10(3):609-11. PubMed ID: 362644
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunologic characterization of the rejection of the allogenic transplanted kidney in pigs with and without immunosuppression].
    Werner M; Keitel R; Schürer KD; Otto U; Klötzer B; Kothe W; Sauer H; Ambrosius H
    Z Exp Chir Transplant Kunstliche Organe; 1986; 19(5):279-92. PubMed ID: 3538686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic correlates of human renal allograft survival.
    Etheredge EE; Sicard GA; Anderson CB
    Transplant Proc; 1979 Mar; 11(1):354-9. PubMed ID: 377655
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody and lymphocyte-mediated immunologic recipient versus donor reactions before and after human renal allotransplantation--a prospective study.
    Grunnet N; Kristensen T
    Transplant Proc; 1978 Sep; 10(3):531-3. PubMed ID: 362630
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring of rejection.
    Stiller CR; Sinclair NR
    Transplant Proc; 1979 Mar; 11(1):343-9. PubMed ID: 377654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplant monitoring: patterns of the immune response.
    Stiller CR; Sinclair NR; Abrahams S; Fung M; Ulan RA; Wallace AC; McGirr D
    Proc Eur Dial Transplant Assoc; 1976; 12():415-22. PubMed ID: 778832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential changes in NK and ADCC effector cell function after organ transplantation in man.
    Hegarty JH; Ramsden CW; Dowd PS; Giles GR; Guillou PJ
    Biomed Pharmacother; 1983; 37(6):266-70. PubMed ID: 6367846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-donor cell-mediated responses. Pretransplant lymphocyte-mediated cytotoxicity (LMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in kidney transplantation.
    Myburgh JA; Smit JA
    Transplant Proc; 1978 Jun; 10(2):425-7. PubMed ID: 354131
    [No Abstract]   [Full Text] [Related]  

  • 14. Alloantibodies and outcomes of deceased donor kidney allografts.
    Cinti P; Pretagostini R; Lai Q; Tamburro ML; Rossi M; Poli L; Berloco P
    Hum Immunol; 2009 Aug; 70(8):651-4. PubMed ID: 19527761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific antibodies in renal allograft recipients. A reevaluation of the 51Cr-release assays comparing fibroblast and lymphoid target cells.
    Halloran PF; Aprile M; Haddad G; Cunningham K; Robinette MA
    Transplantation; 1984 Apr; 37(4):356-8. PubMed ID: 6369664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of in vitro nondonor-specific immune monitoring over donor-specific assays in detecting a prerejection state.
    Kirchoff C; McGeorge M; Thomas FT; Mendez-Picon G; Thomas JM; Lower RR; Lee HM
    Surg Forum; 1979; 30():297-9. PubMed ID: 120020
    [No Abstract]   [Full Text] [Related]  

  • 17. The primacy of humoral antibody (complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity) in concordant xenograft rejection.
    Araneda D; Thomas FT; Ljung T; Cekada E; Pittman K
    Transplant Proc; 1995 Feb; 27(1):268-9. PubMed ID: 7878997
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediction of reversibility of renal allograft rejection.
    Gailiunas P; Busch G; Person A; Carpenter CB; Garovoy MR
    Transplant Proc; 1979 Mar; 11(1):17-9. PubMed ID: 377625
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunologic monitoring in the diagnosis of renal allograft rejection.
    Gailiunas P; Suthanthiran M; Person A; Carpenter CB; Garovoy MR
    Transplant Proc; 1977 Dec; 9(4):1823-5. PubMed ID: 341443
    [No Abstract]   [Full Text] [Related]  

  • 20. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
    Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
    Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.